NCT06382168: An ongoing trial by Delta-Fly Pharma, Inc.
This trial is ongoing. It must report results 11 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06382168 |
|---|---|
| Title | Phase I/II Study of DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 12, 2024 |
| Completion date | March 31, 2025 |
| Required reporting date | March 31, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | April 7, 2025 |
| Days late | None |